Finished product reference
Selenium
Injection · Parenteral · 50 µg/1mL · 10 mL
- List code
- 52276
- Salt form
- Sodium Selenite Pentahydrate
Indications
INDICATIONS AND USAGE For the treatment of tinea versicolor, seborrheic dermatitis of the scalp, and dandruff.
Dosage and administration (summary)
DOSAGE AND ADMINISTRATION See application instructions on rear panel of this bottle. For treatment of dandruff and seborrheic dermatitis: For the usual case, two applications each week for two weeks will afford control. After this, the suspension may be used at less frequent intervals - weekly, every two weeks, or even every 3 or 4 weeks in some cases. The preparation should not be applied more frequently than required to maintain control. For treatment of tinea versicolor: Apply to affected areas and lather with a small amount of water. Allow product to remain on skin for 10 minutes, then rinse the body thoroughly. Repeat this procedure once a day for seven days.
Contraindications
CONTRAINDICATIONS This product should not be used by patients allergic to any of its components.
Warnings and precautions
WARNINGS AND PRECAUTIONS: For External Use Only . Do not use on broken skin or inflamed areas. If allergic reactions occur, discontinue use. Avoid getting shampoo in eyes or in contact with genital area as it may cause irritation and burning. KEEP THIS AND ALL MEDICATIONS OUT OF REACH OF CHILDREN.
Pregnancy
Pregnancy - WHEN USED ON BODY SURFACES FOR THE TREATMENT OF TINEA VERSICOLOR, SELENIUM SULFIDE IS CLASSIFIED AS PREGNANCY CATEGORY "C". Animal reproduction studies have not been conducted with Selenium Sulfide Topical Suspension USP, 2.5% (Lotion).
Storage and supply
Store at 20°-25°C (68°-77°F) .
Source: Selenium Sulfide (Selenium Sulfide) — US FDA prescribing information, 2025-05-31, DailyMed. Summarised and shortened; the full label governs. Iranian registration, indications and labelling may differ.
Other presentations of the same active ingredient
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.